Sign in
CompletedNo phase

Mechanisms of Treatment Effects Using Cultured, Allogeneic Mesenchymal Stromal Stem Cells (MSCs) in Knee Osteoarthritis

Key facts

Who runs it
University Medical Centre Ljubljana
Where
Slovenia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
30 people enrolled
Started
1 Nov 2022
Ended
1 Dec 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Knee aspiration + UCB-MSCs
  • Knee aspiration
Record updated
9 December 2024

Who can take part

Age
50 years to 75 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Patients with end-stage (Kellgren-Lawrence) knee osteoarthritis scheduled for knee arthroplasty
  • Osteoarthritis of primary or post-traumatic etiology

Who cannot take part

  • Anticoagulant therapy
  • Rheumatic diseases
  • Uncontrolled metabolic disorders
  • Heart failure
  • Renal failure
  • Other conditions that may affect immune response or pose additional risk during cell application
  • Secondary arthritis of other etiology
  • Crystalopathies
  • Coagulopathy

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to pharmacologically evaluate the effects of culturued allogeneic umbilical cord blood-derived mesenchymal stromal stem cell (UCB-MSCs) in the treatment of end-stage knee osteoarthritis (Kellgren-Lawrence grade 4) with the analysis of soluble biomarkers and expression of key genes, as well as the evaluation of clinical outcomes with patient-reported outcome measures (PROMs) and recording of potential complications.

Read full original descriptionShow less

Patients will be randomized in the intervention and control groups. In both groups, the knee aspiration will be performed 4-6 weeks prior to the knee arthroplasty to analyse baseline synovial fluid characteristics. The intervention group will receive the injection of UCB-MSCs. All patients will complete PROMs questionnaires and maintain a pain diary on visual analogue scale (VAS) at home until the surgery. On the day of admission to hospital for knee arthroplasty, the same questionnaires will be administered again. During the operative procedures, the samples of synovial fluid, synovial membrane and resected cartilage will be obtained and analysed afterwards.

It is anticipated that the study results will contribute to elucidate the mechanisms of action of MSCs in the treatment of knee osteoarthritis.

The 2 groups in the trial

  • Intervention groupTreatment being tested

    Knee aspiration and the application of UCB-MSCs

    Treatment: Knee aspiration + UCB-MSCs

  • Control groupExisting treatment, for comparison

    Only knee aspiration, without the application of UCB-MSCs

    Treatment: Knee aspiration

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Publications
Record updated
9 December 2024